Kyverna Therapeutics Files 8-K Report
Ticker: KYTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1994702
Sentiment: neutral
Topics: 8-K, financial-statements, disclosure
TL;DR
Kyverna Therapeutics filed an 8-K on Jan 13, 2025, mainly for financial updates and disclosures.
AI Summary
On January 13, 2025, Kyverna Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates that Kyverna Therapeutics is providing updated financial statements and exhibits, and making a Regulation FD disclosure to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, with no indication of significant new risks or events.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-41947 (commission_file_number) — SEC File Number
- 83-1365441 (irs_number) — IRS Employer Identification No.
- 5980 Horton St., STE 550 (address) — Principal Executive Offices
- Emeryville, California (location) — City and State of Principal Executive Offices
- 94608 (zip_code) — Zip Code of Principal Executive Offices
- ( 510 ) 925-2492 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Kyverna Therapeutics, Inc.?
The primary purpose of this 8-K filing, dated January 13, 2025, is to report financial statements and exhibits, and to provide a Regulation FD Disclosure.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing by Kyverna Therapeutics, Inc. was on January 13, 2025.
In which state is Kyverna Therapeutics, Inc. incorporated?
Kyverna Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Kyverna Therapeutics, Inc.?
The SEC file number for Kyverna Therapeutics, Inc. is 001-41947.
What is the business address of Kyverna Therapeutics, Inc.?
The business address of Kyverna Therapeutics, Inc. is 5980 Horton St., STE 550, Emeryville, California, 94608.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-13 07:35:34
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- ea0227480-8k_kyverna.htm (8-K) — 30KB
- ea022748001ex99-1_kyverna.htm (EX-99.1) — 28KB
- ea022748001ex99-2_kyverna.htm (EX-99.2) — 35KB
- ex99-2_001.jpg (GRAPHIC) — 456KB
- ex99-2_002.jpg (GRAPHIC) — 897KB
- ex99-2_003.jpg (GRAPHIC) — 561KB
- ex99-2_004.jpg (GRAPHIC) — 461KB
- ex99-2_005.jpg (GRAPHIC) — 478KB
- ex99-2_006.jpg (GRAPHIC) — 492KB
- ex99-2_007.jpg (GRAPHIC) — 517KB
- ex99-2_008.jpg (GRAPHIC) — 525KB
- ex99-2_009.jpg (GRAPHIC) — 491KB
- ex99-2_010.jpg (GRAPHIC) — 451KB
- ex99-2_011.jpg (GRAPHIC) — 511KB
- ex99-2_012.jpg (GRAPHIC) — 534KB
- ex99-2_013.jpg (GRAPHIC) — 654KB
- ex99-2_014.jpg (GRAPHIC) — 898KB
- ex99-2_015.jpg (GRAPHIC) — 925KB
- ex99-2_016.jpg (GRAPHIC) — 620KB
- ex99-2_017.jpg (GRAPHIC) — 444KB
- ex99-2_018.jpg (GRAPHIC) — 431KB
- ex99-2_019.jpg (GRAPHIC) — 439KB
- ex99-2_020.jpg (GRAPHIC) — 405KB
- ex99-2_021.jpg (GRAPHIC) — 337KB
- ex99-2_022.jpg (GRAPHIC) — 425KB
- ex99-2_023.jpg (GRAPHIC) — 357KB
- ex99-2_024.jpg (GRAPHIC) — 768KB
- ex99-2_025.jpg (GRAPHIC) — 385KB
- ex99-2_026.jpg (GRAPHIC) — 544KB
- ex99-2_027.jpg (GRAPHIC) — 593KB
- ex99-2_028.jpg (GRAPHIC) — 618KB
- ex99-2_029.jpg (GRAPHIC) — 296KB
- 0001213900-25-002831.txt ( ) — 21646KB
- kytx-20250113.xsd (EX-101.SCH) — 3KB
- kytx-20250113_lab.xml (EX-101.LAB) — 33KB
- kytx-20250113_pre.xml (EX-101.PRE) — 22KB
- ea0227480-8k_kyverna_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, Kyverna Therapeutics, Inc. (the "Company") issued a press release announcing the Company's strategic priorities for 2025 and certain anticipated milestones, which will be discussed during a presentation that will be made by the Company's Chief Executive Officer, Warner Biddle, at the 43rd Annual J.P. Morgan Healthcare Conference (the "Conference") at 5:15 p.m. Pacific Time on January 13, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the slides to be used in connection with the Company's presentation at the Conference are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Kyverna Therapeutics, Inc., dated January 13, 2025. 99.2 Kyverna Therapeutics, Inc. Presentation - Pioneering CAR T in Autoimmune Diseases, January 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Warner Biddle Name: Warner Biddle Title: Chief Executive Officer 2